FY2028 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON) – Stock analysts at Wedbush increased their FY2028 earnings per share estimates for Disc Medicine in a research report issued to clients and investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of $7.04 for the year, up from their prior forecast of $6.85. Wedbush has a “Outperform” rating and a $83.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share.

Several other research firms have also issued reports on IRON. Wells Fargo & Company started coverage on Disc Medicine in a research report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research report on Tuesday, October 15th. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a report on Tuesday, November 5th. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $66.00 to $110.00 in a report on Monday, November 4th. Finally, HC Wainwright lifted their price objective on Disc Medicine from $70.00 to $118.00 and gave the company a “buy” rating in a report on Wednesday. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Disc Medicine currently has a consensus rating of “Buy” and a consensus target price of $85.80.

Disc Medicine Trading Down 3.8 %

Disc Medicine stock opened at $60.67 on Thursday. The firm has a market capitalization of $1.80 billion, a P/E ratio of -15.24 and a beta of 0.60. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60. The business has a 50-day moving average of $51.02 and a 200-day moving average of $44.75.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.15.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 7,538 shares of company stock worth $437,875. Corporate insiders own 4.24% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Lord Abbett & CO. LLC acquired a new position in shares of Disc Medicine during the 1st quarter worth approximately $7,429,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Disc Medicine by 59.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after acquiring an additional 353,382 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Disc Medicine during the 2nd quarter worth approximately $34,318,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after acquiring an additional 969,834 shares during the last quarter. Finally, Blue Owl Capital Holdings LP increased its holdings in shares of Disc Medicine by 38.6% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 215,260 shares of the company’s stock worth $9,702,000 after acquiring an additional 60,000 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.